miltefosine has been researched along with allopurinol in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 10 (47.62) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bouton, J; Caljon, G; Cardoso Santos, C; Ferreira de Almeida Fiuza, L; Karalic, I; Maes, L; Mazzarella, MA; Soeiro, MNC; Van Calenbergh, S | 1 |
| Caljon, G; Feijens, PB; Hulpia, F; Karalic, I; Lin, C; Maes, L; Matheeussen, A; Van Calenbergh, S | 1 |
| Gravino, AE; Manna, L; Neglia, G; Picillo, E; Reale, S; Vescio, F; Vitale, F | 1 |
| Gravino, AE; Manna, L; Picillo, E; Reale, S; Vitale, F | 1 |
| Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C | 1 |
| Badino, P; Farca, AM; Ferroglio, E; Miniscalco, B; Monticelli, P; Odore, R; Trisciuoglio, A | 1 |
| Campino, L; Henriques, S; Maia, C; Marques, M; Nunes, M; Rolão, N | 1 |
| Cerrone, A; Corso, R; Galiero, G; Gravino, AE; Manna, L; Muzj, P | 1 |
| Kritsepi-Konstantinou, M; Mylonakis, ME; Oikonomidis, IL; Papadimitriou, S; Psalla, D; Tangalidi, MK | 1 |
| Cordeiro-da-Silva, A; Dantas-Torres, F; Miró, G; Travi, BL | 1 |
| Checa, R; Fariñas, F; Fermín, ML; Flores, L; Fragío, C; Gálvez, R; Marino, V; Martínez-Nevado, E; Miró, G; Montoya, A; Rojo, C; Troyano, A | 1 |
| Cerón, JJ; Checa, R; Daza González, MA; Fermín Rodríguez, M; Fragío Arnold, C; Martínez Subiela, S; Miró, G; Montoya, A; Portero Fuentes, M; Rupérez Noguer, C | 1 |
| Almeida, ADBPF; Ayres, EDCBS; de Carvalho, MR; de Oliveira Martins, DT; de Oliveira, RG; Dias, ÁFLR; Maruyama, FH; Mendonça, AJ; Sousa, VRF; Teixeira, ALS | 1 |
| Alunda, JM; Cuquerella, M; Fontán-Matilla, E; Olías-Molero, AI | 1 |
| Cardoso, L; Leal, RO; Monteiro, M; Pereira da Fonseca, I; Prata, S | 1 |
| Alcover, MM; Fernández, A; Fisa, R; Giner, J; Riera, C; Verde, M; Villanueva-Saz, S; Yzuel, A | 1 |
| Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS | 1 |
| Almeida, ADBPF; Ayres, EDCBS; Barbosa, MEC; Dias, ÁFLR; Dutra, V; Macedo, LFDC; Monteiro, BRG; Nakazato, L; Pazzini, SS; Silva, EBD; Sousa, VRF | 1 |
| Koutinas, AF; Matralis, DT; Papadogiannaki, IE; Papadogiannakis, EI; Papadopoulos, EG | 1 |
| Broere, F; de Jong, MK; Piek, CJ; Rappoldt, A | 1 |
1 review(s) available for miltefosine and allopurinol
| Article | Year |
|---|---|
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Molecular Diagnostic Techniques; Organometallic Compounds; Phosphorylcholine; Point-of-Care Systems; Serologic Tests | 2018 |
3 trial(s) available for miltefosine and allopurinol
| Article | Year |
|---|---|
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Retrospective Studies | 2015 |
Intracellular IFN-γ and IL-4 levels of CD4 + and CD8 + T cells in the peripheral blood of naturally infected (Leishmania infantum) symptomatic dogs before and following a 4-week treatment with miltefosine and allopurinol: a double-blinded, controlled and
Topics: Allopurinol; Animals; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Dog Diseases; Dogs; Interferon-gamma; Interleukin-4; Leishmania infantum; Leishmaniasis, Visceral | 2023 |
17 other study(ies) available for miltefosine and allopurinol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Revisiting Pyrazolo[3,4-
Topics: Animals; Chagas Disease; Drug Design; Drug Stability; Humans; Leishmania infantum; Male; Mice; Microsomes, Liver; Molecular Structure; Nucleosides; Pyrazoles; Pyrimidines; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2021 |
Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Leishmania; Leishmaniasis; Mice; Nucleosides; Purine Nucleosides; Purines; Ribonucleosides | 2022 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Treatment Outcome; Zoonoses | 2009 |
Interferon-gamma (INF-gamma), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; DNA, Protozoan; Dog Diseases; Dogs; Interferon-gamma; Interleukin-4; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2008 |
Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Synergism; Fluoroquinolones; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2012 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Dog Diseases; Dogs; Drug Combinations; Humans; Immunocompetence; Immunocompromised Host; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine | 2013 |
Nodular granulomatous glossitis as the sole clinical sign in canine leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Fluorescent Antibody Technique, Indirect; Glossitis; Immunohistochemistry; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Tongue | 2016 |
First report of Leishmania infantum infection in the endangered orangutan (Pongo pygmaeus pygmaeus) in Madrid, Spain.
Topics: Allopurinol; Animals; Diagnosis, Differential; Disease Outbreaks; Endangered Species; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Pongo pygmaeus; Psychodidae; Spain | 2018 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2019 |
Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Cytokines; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2020 |
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020).
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; Drug Therapy; Humans; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Phosphorylcholine; Publications | 2021 |
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.
Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Humans; Knowledge; Leishmania infantum; Leishmaniasis; Male; Middle Aged; Phosphorylcholine; Portugal; Practice Guidelines as Topic; Surveys and Questionnaires; Veterinarians | 2021 |
Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up.
Topics: Allopurinol; Animals; Ferrets; Follow-Up Studies; Leishmania infantum; Phosphorylcholine | 2021 |
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Female; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2021 |
Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2022 |
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Meglumine Antimoniate; Prognosis; Recurrence; Urea | 2023 |